Aprea Therapeutics Inc
APRE0.944USD
-0.001-0.10%
Market hours （ET）Quotes delayed by 15 min
5.65MMarket Cap
LossP/E TTM
More Details of Aprea Therapeutics Inc Company
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Aprea Therapeutics Inc Info
Ticker SymbolAPRE
Company nameAprea Therapeutics Inc
IPO dateOct 03, 2019
CEOGilad (Oren)
Number of employees8
Security typeOrdinary Share
Fiscal year-endOct 03
Address3805 Old Easton Road
CityDOYLESTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code18902
Phone12159484119
Websitehttps://www.aprea.com/
Ticker SymbolAPRE
IPO dateOct 03, 2019
CEOGilad (Oren)
Company Executives of Aprea Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marc Duey
Mr. Marc Duey
Independent Director
Independent Director
255.71K
+21459.00%
Dr. Rifat Pamukcu, M.D.
Dr. Rifat Pamukcu, M.D.
Independent Director
Independent Director
18.51K
+1045.00%
Mr. John P. Hamill
Mr. John P. Hamill
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
17.63K
+5000.00%
Dr. Richard Peters, M.D., Ph.D.
Dr. Richard Peters, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.07K
+1045.00%
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
1.04K
+1045.00%
Dr. Jean-Pierre Bizzari, M.D.
Dr. Jean-Pierre Bizzari, M.D.
Independent
Independent
1.04K
+1045.00%
Dr. Bernd R. Seizinger, M.D., Ph.D.
Dr. Bernd R. Seizinger, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John Bell (Jack) Henneman, III
Mr. John Bell (Jack) Henneman, III
Lead Independent Director
Lead Independent Director
--
--
Mr. Michael J. Grissinger
Mr. Michael J. Grissinger
Independent Director
Independent Director
--
--
Dr. Oren Gilad, Ph.D.
Dr. Oren Gilad, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Marc Duey
Mr. Marc Duey
Independent Director
Independent Director
255.71K
+21459.00%
Dr. Rifat Pamukcu, M.D.
Dr. Rifat Pamukcu, M.D.
Independent Director
Independent Director
18.51K
+1045.00%
Mr. John P. Hamill
Mr. John P. Hamill
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
17.63K
+5000.00%
Dr. Richard Peters, M.D., Ph.D.
Dr. Richard Peters, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.07K
+1045.00%
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
1.04K
+1045.00%
Dr. Jean-Pierre Bizzari, M.D.
Dr. Jean-Pierre Bizzari, M.D.
Independent
Independent
1.04K
+1045.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lytton (Laurence W)
9.75%
AIGH Capital Management, LLC.
5.46%
Gilad (Oren Ph.D.)
4.76%
Sphera Funds Management Ltd.
3.86%
Duey (Marc)
3.66%
Other
72.51%
Shareholders
Shareholders
Proportion
Lytton (Laurence W)
9.75%
AIGH Capital Management, LLC.
5.46%
Gilad (Oren Ph.D.)
4.76%
Sphera Funds Management Ltd.
3.86%
Duey (Marc)
3.66%
Other
72.51%
Shareholder Types
Shareholders
Proportion
Individual Investor
21.66%
Hedge Fund
11.67%
Private Equity
6.05%
Investment Advisor
3.36%
Investment Advisor/Hedge Fund
3.20%
Research Firm
1.40%
Other
52.66%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
46
1.62M
23.17%
-593.30K
2025Q3
48
1.62M
37.03%
-196.66K
2025Q2
48
1.82M
43.46%
-447.20K
2025Q1
50
1.95M
41.99%
-363.29K
2024Q4
59
2.08M
42.95%
-14.79K
2024Q3
61
2.21M
40.47%
-82.86K
2024Q2
68
2.41M
38.57%
+438.42K
2024Q1
72
1.75M
18.93%
+718.60K
2023Q4
75
958.62K
26.82%
+49.53K
2023Q3
93
908.66K
29.81%
-4.40K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lytton (Laurence W)
681.84K
9.75%
+681.84K
--
Nov 13, 2025
AIGH Capital Management, LLC.
382.06K
5.46%
--
--
Sep 30, 2025
Gilad (Oren Ph.D.)
333.19K
4.76%
+4.04K
+1.23%
Apr 10, 2025
Sphera Funds Management Ltd.
270.00K
3.86%
--
--
Sep 30, 2025
Duey (Marc)
255.71K
3.66%
+21.46K
+9.16%
Dec 10, 2025
Nantahala Capital Management, LLC
205.76K
2.94%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
158.24K
2.26%
-15.60K
-8.98%
Sep 30, 2025
Worth Venture Partners, LLC
157.24K
2.25%
--
--
Sep 30, 2025
Dafna Capital Management, LLC
137.17K
1.96%
--
--
Sep 30, 2025
Sio Capital Management, LLC
112.22K
1.6%
-167.15K
-59.83%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 10, 2023
Merger
20→1
Feb 10, 2023
Merger
20→1
Feb 10, 2023
Merger
20→1
Feb 10, 2023
Merger
20→1
Date
Type
Ratio
Feb 10, 2023
Merger
20→1
Feb 10, 2023
Merger
20→1
Feb 10, 2023
Merger
20→1
Feb 10, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Aprea Therapeutics Inc?
The top five shareholders of Aprea Therapeutics Inc are:
Lytton (Laurence W) holds 681.84K shares, accounting for 9.75% of the total shares.
AIGH Capital Management, LLC. holds 382.06K shares, accounting for 5.46% of the total shares.
Gilad (Oren Ph.D.) holds 333.19K shares, accounting for 4.76% of the total shares.
Sphera Funds Management Ltd. holds 270.00K shares, accounting for 3.86% of the total shares.
Duey (Marc) holds 255.71K shares, accounting for 3.66% of the total shares.
Lytton (Laurence W) holds 681.84K shares, accounting for 9.75% of the total shares.
AIGH Capital Management, LLC. holds 382.06K shares, accounting for 5.46% of the total shares.
Gilad (Oren Ph.D.) holds 333.19K shares, accounting for 4.76% of the total shares.
Sphera Funds Management Ltd. holds 270.00K shares, accounting for 3.86% of the total shares.
Duey (Marc) holds 255.71K shares, accounting for 3.66% of the total shares.
What are the top three shareholder types of Aprea Therapeutics Inc?
The top three shareholder types of Aprea Therapeutics Inc are:
Lytton (Laurence W)
AIGH Capital Management, LLC.
Gilad (Oren Ph.D.)
Lytton (Laurence W)
AIGH Capital Management, LLC.
Gilad (Oren Ph.D.)
How many institutions hold shares of Aprea Therapeutics Inc (APRE)?
As of 2025Q4, 46 institutions hold shares of Aprea Therapeutics Inc, with a combined market value of approximately 1.62M, accounting for 23.17% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -13.86%.
What is the biggest source of revenue for Aprea Therapeutics Inc?
In --, the -- business generated the highest revenue for Aprea Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
